Grace Therapeutics Inc. (GRCE)
3.50
-0.24 (-6.42%)
At close: Jan 28, 2025, 2:07 PM
Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 7, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center Princeton, New Jersey United States | |
| Website | https://www.acastipharma.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US00439U1043 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer & Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer |
| Robert J. DelAversano CPA | Vice President of Finance and Principal Financial & Accounting Officer |